Interview with Carlos Kiffer, President, GC-2
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
Address: Av. Nações Unidas, 12.399, 12º andar, cj 125 A, Edifício Landmark CEP 04578-000, São Paulo – SP,Brazil
Tel: (11) 3528 7406
Web: http://www.gcdois.com.br/
GC-2, in tune with the surge in R&D for pharmaceutical products in the region, provides intelligent solutions for this interdisciplinary scenario.
The natural growth of pharmaceuticals in the region, including herbal medicines and biotechnology products, has caused a parallel demand for project management. However, GC-2 is not just one more consulting firm. We bring the Project Management Office concept to pharmaceutical R&D.
In order to strengthen the strategic decision making process in pharmaceutical drug and product development, GC-2 offers its clients alternatives for the technical and commercial scientific monitoring of their developments:
Technical and scientific viability and patentability, Conceptualization & positioning, Structuring & management, Production and quality insurance interface, Pre-clinical pharmacological development interface, Pre-clinical toxicological development interface, Clinical development, Public agency interface, Antimicrobial development
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
Ricardo Lourenço, VP-Managing Director of Lupin in Brazil has been in charge of implementing the take over of Medquímica by Lupin. In this interview he explains Brazil is a land…
Josiel Florenzano, managing director of Lundbeck Brazil and South Cone, provides us with an overview of the main dynamics shaping the Brazilian CNS market as well as the opportunities he…
Neide Kawabata, president of B Braun Brazil, shares B Braun’s long track record of success and commitment to Brazil, the innovations they continue to bring to the market, and the…
Dr. Ogari Pacheco, president of the Board of Directors for Cristália, highlights the unique journey for Cristália over the past 45 years, as one of the most innovative local pharma…
Andrew Simpson, Scientific Director of Orygen, elaborates on the innovative collaboration model his company is taking part in to develop biotechnologies in Brazil, the importance of developing affordable treatments for…
Jaime Rabi, director of Microbiológica, documents the unique development path of the company and its pioneering contribution to the production of antiretroviral medicines in Brazil, as well as its international…
Heraldo Marchezini, CEO of the Brazilian biotech company Biomm and one of the leading executives in the Brazilian biopharmaceutical sector, provides insights into the eye-catching international partnerships recently signed by…
Marco Fireman, vice-minister and chairman of the National Commission for the Incorporation of Technologies (CONITEC); a board that advises the Brazilian Ministry of Health on the inclusion of new health…
Samuel Mauricio, vice-president for Brazil at Octapharma, one of the largest human protein manufacturers in the world, provides an insightful analysis of the Brazilian plasma market, demonstrating Octapharma’s remarkable willingness…
Nelson Mussolini, executive president of the syndicate of the pharmaceutical industry in the State of Sao Paulo (Sindusfarma), which represents around 95 percent of all pharmaceutical marketing in the country…
Antonio Britto, the executive president of Interfarma, the main association gathering together local and international innovators in Brazil, provides insights into some of the hottest topics in Brazil’s pharmaceutical sector,…
Eduardo Martins, president director of Pharlab, provides insights into the “2020 vision” that has been driving the eye-catching development of this ambitious domestic company and documents how Pharlab is leveraging…
See our Cookie Privacy Policy Here